Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and T-DM1 in HER2-positive Metastatic Breast Cancer
NCT04351230Phase 2Withdrawn
- Sponsor
- Academic and Community Cancer Research United
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in HER2-positive breast cancer, breast cancer, sponsored by Academic and Community Cancer Research United. Planned start Nov 2020; status: withdrawn.
02
Drugs
abemaciclib
03
Conditions
HER2-positive breast cancerbreast cancer
Beyond the preview
Go deeper on NCT04351230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351230.